2022
Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort
Lu Y, Van Zandt M, Liu Y, Li J, Wang X, Chen Y, Chen Z, Cho J, Dorajoo SR, Feng M, Hsu MH, Hsu JC, Iqbal U, Jonnagaddala J, Li YC, Liaw ST, Lim HS, Ngiam KY, Nguyen PA, Park RW, Pratt N, Reich C, Rhee SY, Sathappan SMK, Shin SJ, Tan HX, You SC, Zhang X, Krumholz HM, Suchard MA, Xu H. Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort. JAMA Network Open 2022, 5: e223877. PMID: 35323951, PMCID: PMC8948532, DOI: 10.1001/jamanetworkopen.2022.3877.Peer-Reviewed Original ResearchConceptsDual combination therapyUse of ACEIAntihypertensive drug classesProportion of patientsKhoo Teck Puat HospitalCombination therapyUniversity Hospital databaseHospital databaseDrug classesDual combinationSouth Western Sydney Local Health DistrictWestern Sydney Local Health DistrictPatients age 65 yearsSydney Local Health DistrictElectronic health record databasePatients age 18Local Health DistrictAge 65 yearsTreatment of hypertensionHealth record databaseARB monotherapyTreatment escalationAdult patientsCohort studyCombination regimen
2020
Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
Morales DR, Conover MM, You SC, Pratt N, Kostka K, Duarte-Salles T, Fernández-Bertolín S, Aragón M, DuVall SL, Lynch K, Falconer T, van Bochove K, Sung C, Matheny ME, Lambert CG, Nyberg F, Alshammari TM, Williams AE, Park RW, Weaver J, Sena AG, Schuemie MJ, Rijnbeek PR, Williams RD, Lane JCE, Prats-Uribe A, Zhang L, Areia C, Krumholz HM, Prieto-Alhambra D, Ryan PB, Hripcsak G, Suchard MA. Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. The Lancet Digital Health 2020, 3: e98-e114. PMID: 33342753, PMCID: PMC7834915, DOI: 10.1016/s2589-7500(20)30289-2.Peer-Reviewed Original ResearchAngiotensin receptor blockersCalcium channel blockersAcute respiratory distress syndromeAcute kidney injuryHospital admissionRespiratory distress syndromeCOVID-19 diagnosisKidney injuryDistress syndromeDrug classesCohort analysisCOVID-19Renin-angiotensin system blockersThiazide-like diureticsBaseline patient characteristicsUse of ACEIsPost-authorisation studiesUK National InstituteRelative risk differenceNational InstituteCombination useMedical Research CouncilAustralian National HealthElectronic health recordsAntihypertensive users
2019
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. The Lancet 2019, 394: 1816-1826. PMID: 31668726, PMCID: PMC6924620, DOI: 10.1016/s0140-6736(19)32317-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersChildCohort StudiesComparative Effectiveness ResearchDatabases, FactualDiureticsEvidence-Based MedicineFemaleHeart FailureHumansHypertensionMaleMiddle AgedMyocardial InfarctionStrokeYoung AdultConceptsNon-dihydropyridine calcium channel blockersCalcium channel blockersThiazide-like diureticsChannel blockersEnzyme inhibitorsDrug classesHazard ratioCurrent guidelinesFirst-line antihypertensive drug classesComparative effectivenessFirst-line drug classesNew-user cohort designDihydropyridine calcium channel blockerElectronic health record databaseFirst-line classesAngiotensin receptor blockersAntihypertensive drug classesAcute myocardial infarctionHealth record databaseReal-world evidenceMedical Research CouncilMillions of patientsAustralian National HealthOptimal monotherapyReceptor blockers
2017
Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. JAMA 2017, 317: 1854-1863. PMID: 28492899, PMCID: PMC5815036, DOI: 10.1001/jama.2017.5150.Peer-Reviewed Original ResearchConceptsNovel therapeuticsSafety eventsAccelerated approvalTherapeutic characteristicsUS FoodDrug AdministrationFDA approvalInitial regulatory approvalClinician decision makingNew safety risksMedian followCohort studyMedian timeMultivariable analysisBoxed warningDrug classesMAIN OUTCOMEClinical practicePostmarket periodPsychiatric diseasesPriority reviewTherapeutic areasOrphan statusPsychiatric therapeuticsBiologics
2016
Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study
Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. The BMJ 2016, 354: i4189. PMID: 27540015, PMCID: PMC4989280, DOI: 10.1136/bmj.i4189.Peer-Reviewed Original ResearchConceptsHospital referral regionsOral anticoagulantsReferral regionsDiabetes drugsDrug classesGreater prescribingMedicare Part D beneficiariesAdditional daysPart D beneficiariesMedicare Part D prescriptionsCross-sectional analysisSectional ecological studyMedicare Part DPart D prescriptionsManufacturers of pharmaceuticalsPrescribingAnticoagulantsPhysiciansDrugsPart DEducational materialsSectional analysisStudy limitationsConsulting feesAssociation